Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Influenza A Virus, H3N2 Subtype Infections Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Influenza A Virus, H3N2 Subtype Infections Overview | 11 | 1 |
| Pipeline Products for Influenza A Virus, H3N2 Subtype Infections Comparative Analysis | 12 | 1 |
| Influenza A Virus, H3N2 Subtype Infections Therapeutics under Development by Companies | 13 | 2 |
| Influenza A Virus, H3N2 Subtype Infections Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Influenza A Virus, H3N2 Subtype Infections Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Influenza A Virus, H3N2 Subtype Infections Products under Development by Companies | 19 | 2 |
| Influenza A Virus, H3N2 Subtype Infections Products under Investigation by Universities/Institutes | 21 | 1 |
| Influenza A Virus, H3N2 Subtype Infections Companies Involved in Therapeutics Development | 22 | 19 |
| AbbVie Inc | 22 | 1 |
| AIMM Therapeutics B.V. | 23 | 1 |
| Aphios Corporation | 24 | 1 |
| Celltrion, Inc. | 25 | 1 |
| FluGen, Inc. | 26 | 1 |
| Glide Pharmaceutical Technologies Limited | 27 | 1 |
| ILiAD Biotechnologies, LLC | 28 | 1 |
| Inovio Pharmaceuticals, Inc. | 29 | 1 |
| Johnson &Johnson | 30 | 1 |
| Medicago Inc. | 31 | 1 |
| MedImmune, LLC | 32 | 1 |
| Mucosis B.V. | 33 | 1 |
| NanoViricides, Inc. | 34 | 1 |
| OPKO Health, Inc. | 35 | 1 |
| Sarepta Therapeutics, Inc. | 36 | 1 |
| Takeda Pharmaceutical Company Limited | 37 | 1 |
| VBI Vaccines Inc. | 38 | 1 |
| Visterra, Inc. | 39 | 1 |
| Zydus Cadila Healthcare Limited | 40 | 1 |
| Influenza A Virus, H3N2 Subtype Infections Therapeutics Assessment | 41 | 10 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Combination Products | 42 | 1 |
| Assessment by Target | 43 | 2 |
| Assessment by Mechanism of Action | 45 | 2 |
| Assessment by Route of Administration | 47 | 2 |
| Assessment by Molecule Type | 49 | 2 |
| Drug Profiles | 51 | 46 |
| APP-0205 Drug Profile | 51 | 1 |
| APP-309 Drug Profile | 52 | 1 |
| Aspidasept Drug Profile | 53 | 1 |
| C-05 Drug Profile | 54 | 1 |
| CR-8020 Drug Profile | 55 | 1 |
| CR-9114 Drug Profile | 56 | 1 |
| CTP-27 Drug Profile | 57 | 1 |
| Fluad (quadrivalent) Drug Profile | 58 | 1 |
| FluGEM Drug Profile | 59 | 1 |
| Gamma-Flu Drug Profile | 60 | 1 |
| influenza [strain A/H3N2] (monovalent) vaccine Drug Profile | 61 | 1 |
| influenza [strain A/H3N2] vaccine Drug Profile | 62 | 1 |
| influenza [strain A/H3N2] vaccine Drug Profile | 63 | 1 |
| influenza [strain A/H3N2] vaccine Drug Profile | 64 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine Drug Profile | 65 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile | 66 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile | 67 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine Drug Profile | 68 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile | 69 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine Drug Profile | 70 | 3 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile | 73 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine Drug Profile | 74 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile | 75 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile | 76 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile | 77 | 1 |
| JNJ-872 Drug Profile | 78 | 2 |
| NEO-8877 Drug Profile | 80 | 1 |
| NVINF-1 Drug Profile | 81 | 4 |
| NVINF-2 Drug Profile | 85 | 3 |
| pertussis [strain BPZE1] vaccine Drug Profile | 88 | 2 |
| PNSIA-28 Drug Profile | 90 | 1 |
| radavirsen Drug Profile | 91 | 2 |
| REDEE FLU Drug Profile | 93 | 1 |
| Small Molecules for RSV and Influenza A Infections Drug Profile | 94 | 1 |
| VIS-410 Drug Profile | 95 | 2 |
| Influenza A Virus, H3N2 Subtype Infections Dormant Projects | 97 | 1 |
| Influenza A Virus, H3N2 Subtype Infections Product Development Milestones | 98 | 3 |
| Featured News &Press Releases | 98 | 1 |
| Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season | 98 | 1 |
| Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 | 98 | 1 |
| Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza | 99 | 2 |
| Appendix | 101 | 2 |
| Methodology | 101 | 1 |
| Coverage | 101 | 1 |
| Secondary Research | 101 | 1 |
| Primary Research | 101 | 1 |
| Expert Panel Validation | 101 | 1 |
| Contact Us | 101 | 1 |
| Disclaimer | 102 | 1 |